New combo therapy shows promise for rare, aggressive cancer
NCT ID NCT06232564
First seen Jan 26, 2026 · Last updated Jun 11, 2026 · Updated 28 times
Summary
This study tests a new treatment for people with advanced high-grade neuroendocrine tumors (a rare and fast-growing cancer). Participants first receive chemotherapy (etoposide and carboplatin) plus an immunotherapy drug (pembrolizumab), followed by a maintenance therapy of pembrolizumab and lenvatinib. The goal is to see if this combination shrinks tumors and is safe. The study involves 20 adults who have not had chemotherapy for their metastatic disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
Conditions
Explore the condition pages connected to this study.